Neffy, Epinephrine Nasal Spray: The Needle-Free Emergency Treatment for Anaphylaxis

Anaphylaxis is an acute, life-threatening, multisystem condition caused by the abrupt release of mediators by mast cells and basophils. Epinephrine Autoinjectors (EAIs) are used for treating anaphylaxis. Low prescription fulfillment rates, non-carrying behavior and needle-phobia prevent them from being as useful as they could be. Growing interest has been seen in creating simple-to-use, needle-free delivery systems. Recently, a new therapeutic option for anaphylaxis has emerged: Neffy, an epinephrine nasal spray. The FDA has approved neffy, a needle-free, easy-to-carry epinephrine delivery method for severe allergies. This has the potential to reduce time of administration, leading to better clinical outcomes and improved quality of life for patients. An overview of Neffy, including its development approach and review of available clinical data is given in this review.